HLX-22 is a humanized monoclonal antibody targeting HER2. When used in combination with trastuzumab, HLX-22 can induce apoptosis in HER2-overexpressing breast and gastric cancer cells. It also exhibits potent antitumor activity against advanced solid tumors.
CAS Number:
[2851060-90-5]
Target:
EGFR
* VAT and and shipping costs not included. Errors and price changes excepted